Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This study evaluates the use of vectors based on adeno-associated viruses (AAVs) to noninvasively deliver genes to airway epithelial cells as a means for achieving systemic administration of therapeutic proteins. We intranasally delivered AAV vectors to mice in which the same AAV2 genome encoding a cellular marker was packaged in capsids from AAV1, 2, or 5 (AAV2/1, AAV2/2, or AAV2/5, respectively). Gene expression levels achieved in both airways and alveoli were higher with AAV2/5 than with AAV2/1 and were undetectable with AAV2/2. The same set of vectors encoding a secreted therapeutic protein, erythropoietin (Epo), under the control of a lung-specific promoter (CC10) was intranasally delivered to mice, resulting in polycythemia with the highest levels of serum Epo obtained with AAV2/5 vectors. After a single intranasal administration of this vector, secretion of Epo was documented for 150 days. Similarly, intranasal administration of an AAV2/5-CC10-factor IX vector resulted in secretion of functional recombinant protein in the bloodstream of hemophiliac, factor IX-deficient mice. In addition, we demonstrate successful readministration of AAV2/5 to the lung 5 months after the first delivery of the same vector. In conclusion, we show that intranasal administration of AAV vectors results in efficient gene transfer to the lung only when the vector contains the AAV5 capsid and that this noninvasive route of administration results in sustained secretion of therapeutic proteins in the bloodstream.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Self-citationGene therapy vectors based on adeno-associated virus type 1
Xiao, W., Chirmule, N., Berta, S. C., McCullough, B., Gao, G., & Wilson, J. M. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3994-4003.1999 · Cited by 541 · cited 1×
“Recombinant AAV2, AAV2/5, and AAV2/1 viruses were produced according to protocols described elsewhere (6, 19, 22).”
MethodSelf-citationSamulski, R. J., Berns, K. I., Tan, M., & Muzyczka, N. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.6.2077 · Cited by 466
Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 1×
“Although there has been some success using AAV2-based vectors in the lung (13), most experiments with AAV2 gene delivery to airway epithelial cells from the luminal side have been disappointing (14, 15).”
BackgroundChao, H., Liu, Y., Rabinowitz, J., Li, C., Samulski, R. J., & Walsh, C. E. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0219 · Cited by 366 · cited 1×
“In contrast, comparative experiments in muscle have shown that AAV2/1 is most efficient (28).”
BackgroundHalbert, C. L., Rutledge, E. A., Allen, J. M., Russell, D. W., & Miller, A. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.3.1524-1532.2000 · Cited by 259 · cited 2×
“readministration of AAV-based vectors requires the use of alternate AAV serotypes (12, 22) or transient immunosuppression (40), which would be impractical in the clinical setting.”
BackgroundHalbert, C. L., Standaert, T. A., Wilson, C. B., & Miller, A. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9795-9805.1998 · Cited by 203
Cited by
Grimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
Grimm, D., Kay, M. A., & Kleinschmidt, J. A. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00095-9 · Cited by 344
“, capsids of AAV serotypes other than 2 bearing a recombinant AAV-2 genome) exhibit host ranges largely different from AAV-2, as found in tissues such as skeletal muscle [6–8], retina [9], lung [10,11], or CNS [12] or in hematopoietic cells [13].”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
Various AAV Serotypes and Their Applications in Gene Therapy: An Overview
Issa, S. S., Shaimardanova, A. A., Solovyeva, V. V., & Rizvanov, A. A. (2023) · Cells · doi:10.3390/cells12050785 · Cited by 313
Auricchio, A., Hildinger, M., O'Connor, E., Gao, G.-P., & Wilson, J. M. (2001) · Human Gene Therapy · doi:10.1089/104303401450988 · Cited by 297
Self-citation
Metadata
- Authors
- Auricchio, A., O’Connor, E., Weiner, D., Gao, G.-P., Hildinger, M., Wang, L., Calcedo, R., & Wilson, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-08-15
- Volume
- 110
- Issue
- 4
- Pages
- 499-504
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2042147187
- Cited by
- 136
- References
- 7
- FWCI
- 7.17
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. https://app.cochat.ai/papers/10.1172/jci15780
- The paper
- Auricchio, A., O’Connor, E., Weiner, D., Gao, G.-P., Hildinger, M., Wang, L., Calcedo, R., & Wilson, J. M. (2002). Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. Journal of Clinical Investigation. https://doi.org/10.1172/jci15780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.